GBM AGILE: Changing the way we fight cancer!
GBM AGILE is a revolutionary clinical trial platform designed for patients battling the deadliest brain cancer, glioblastoma. The AGILE trial design is a model for drug development to support patients with other rare cancers and diseases.
Clinical and scientific leadership for GBM recognized the need to advance effective treatments for patients with this incurable and universally fatal cancer. They joined forces to create an innovative clinical trial platform to accelerate the evaluation of new treatments for GBM. By efficiently testing multiple drugs and drug combinations simultaneously, GBM AGILE serves as a patient centered initiative to improve treatment options for patients.
As a founding member of GBM AGILE, NFCR has taken a leading role in this unprecedented global effort. With help from our generous supporters, rapid progress is being made–new trial sites are opening in the US and around the world, patients are being enrolled and receiving the most promising treatments. Your support is crucial—together we can conquer the most challenging cancers and diseases.
A Hero’s Last Battle
Before losing his battle with brain cancer, former U.S Marine officer Dwayne Osgood, sent an inspiring message to the cancer community. Through participation in NFCR’s Play4TheCure program, Dwayne and his teammates raised over $38,000 to support GBM AGILE. Throughout his journey with cancer, Dwayne continued to remain positive and turned his unexpected challenge into a remarkable opportunity to make a significant impact on cancer research.
The diagnosis of a malignant brain tumor is heart-wrenching for patients and families. New and validated therapies are desperately needed. GBM AGILE holds great promise for the future.Sujuan Ba, Ph.D., NFCR President & CEO
GBM AGILE is among the most innovative and paradigm-shifting trial platforms in the world, and one that provides huge impacts for brain cancer patients.Webster Cavenee, Ph.D., NFCR Scientific Advisory Board Chair
GBM AGILE provides increasing opportunities for patients to receive more innovative drugs, and it shortens the time to see treatment impact on patient survival.W.K. Alfred Yung, M.D, University of Texas MD Anderson Cancer Center